EYP-1901
Total Payments
$16.7M
Transactions
1,043
Doctors
213
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $7.4M | 751 | 174 |
| 2023 | $8.7M | 251 | 81 |
| 2022 | $658,049 | 35 | 0 |
| 2020 | $13,669 | 6 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15.6M | 264 | 93.6% |
| Consulting Fee | $938,593 | 281 | 5.6% |
| Travel and Lodging | $86,701 | 179 | 0.5% |
| Food and Beverage | $39,768 | 310 | 0.2% |
| Gift | $1,425 | 8 | 0.0% |
| Education | $39.98 | 1 | 0.0% |
Payments by Type
Research
$15.6M
264 transactions
General
$1.1M
779 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD | EyePoint Pharmaceuticals US, Inc. | $11.4M | 2 |
| A Phase 2, Multicenter, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) | EyePoint Pharmaceuticals US, Inc. | $2.3M | 1 |
| A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME) | EyePoint Pharmaceuticals US, Inc. | $880,259 | 2 |
| A 2-year Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD | EyePoint Pharmaceuticals US, Inc. | $598,527 | 0 |
| A phase 1, Multicenter, Prospective, Open-Label, Dose escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in subjects with Wet AMD | EyePoint Pharmaceuticals US, Inc. | $394,711 | 0 |
Top Doctors Receiving Payments for EYP-1901 — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Ophthalmology | Scottsdale, AZ | $6,256 | 7 |
| , M.D | Ophthalmology | Chicago, IL | $6,220 | 7 |
| , M.D | Ophthalmology | Durham, NC | $5,917 | 2 |
| , MD | Ophthalmology | Orange, CA | $5,641 | 9 |
| , MD, MPH | Ophthalmology | Chicago, IL | $5,546 | 10 |
| , M.D | Ophthalmology | Oak Forest, IL | $5,408 | 7 |
| , MD | Retina Specialist | Palm Harbor, FL | $4,912 | 8 |
| , M.D | Retina Specialist | Santa Barbara, CA | $4,846 | 4 |
| , MD | Retina Specialist | Miami, FL | $4,640 | 3 |
| , MD | Retina Specialist | Melbourne, FL | $4,568 | 2 |
| , M.D | Ophthalmology | Durham, NC | $4,513 | 6 |
| , M.D | Ophthalmology | Wesley Chapel, FL | $4,123 | 7 |
| , M.D | Ophthalmology | Reno, NV | $4,000 | 4 |
| , MD | Ophthalmology | Boston, MA | $3,981 | 4 |
| , MD | Ophthalmology | Houston, TX | $3,856 | 6 |
| , M.D | Ophthalmology | Cleveland, OH | $3,819 | 3 |
| , M.D | Ophthalmology | Nashville, TN | $3,805 | 5 |
| , M.D | Specialist | Santa Barbara, CA | $3,723 | 5 |
| , M.D | Ophthalmology | Waltham, MA | $3,700 | 1 |
| , M.D | Ophthalmology | Philadelphia, PA | $3,696 | 7 |
| , M.D | Retina Specialist | Cleveland, OH | $3,648 | 6 |
| , M.D | Ophthalmology | Lutherville, MD | $3,648 | 3 |
| , M.D | Retina Specialist | Burleson, TX | $3,492 | 5 |
| , MD | Retina Specialist | Atlanta, GA | $3,451 | 8 |
| , MD | Ophthalmology | Pasadena, CA | $3,404 | 6 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $16.7M
- Total Doctors 213
- Transactions 1,043
About EYP-1901
EYP-1901 is a drug associated with $16.7M in payments to 213 healthcare providers, recorded across 1,043 transactions in the CMS Open Payments database. The primary manufacturer is EyePoint Pharmaceuticals US, Inc..
Payment data is available from 2020 to 2024. In 2024, $7.4M was paid across 751 transactions to 174 doctors.
The most common payment nature for EYP-1901 is "Unspecified" ($15.6M, 93.6% of total).
EYP-1901 is associated with 5 research studies, including "A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Wet AMD" ($11.4M).